Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of RO5190591 (Danoprevir) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01164488
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01164007
- Locations
- 🇮🇹
Istituto Europeo Di Oncologia, Milano, Lombardia, Italy
A Study of RO5045337 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO5045337
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT01164033
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 347
- Registration Number
- NCT01161173
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01159171
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01156961
A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Procedure: DialysisDrug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 86
- Registration Number
- NCT01156363
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT01153971
- Locations
- 🇮🇹
Universita' Degli Studi La Sapienza-Ist.Di Ematologia;Dip. Biotecnologie Cel CELLULARI ED EMATOLOGIA, Roma, Lazio, Italy
🇮🇹Ospedale Civile; Divisione Di Oncologia, Pescara, Abruzzo, Italy
🇮🇹A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica, Modena, Emilia-Romagna, Italy
A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01153984
- Locations
- 🇷🇴
Spitalul de Boli Cronice Sf. Luca, Bucharest, Romania
🇷🇴Emergency University Bucharest Hospital; Oncology Department, Bucharest, Romania
🇷🇴ONCOMED - Medical Centre, Timisoara, Romania
A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: PlaceboDrug: RO5024048
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT01152671
© Copyright 2025. All Rights Reserved by MedPath